Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
A judge has declined to order US-based animal genomics company Scidera to file a position statement in its bovine gene patent infringement suit and said she was “running out of patience” after unsuccessful strike-out and summary dismissal applications by the defendants.
Animal drug company Zoetis has lost its bid for summary dismissal of claims that it infringed US-based animal genomics company Scidera’s bovine gene patent, with a judge saying its novel arguments were not so clear-cut and needed to be worked out at trial.
Samsung Bioepis has successfully opposed Janssen’s bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
A judge has ordered tech company Vehicle Management Systems to hurry up and choose between damages or an account of profits in its IP dispute with the city of Melbourne over a sensor-based system for timing parked vehicles.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
A German bottling machine manufacturer has successfully opposed PepsiCo’s patent application for a filling system, after arguing the claims were obvious.
Sandoz has accused Amgen of ‘dragging the chain’ as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.